نتایج جستجو برای: brafv600e
تعداد نتایج: 835 فیلتر نتایج به سال:
UNLABELLED Patients with early stage, radial growth phase (RGP) melanoma have a 97% survival rate; however, when the melanoma progresses to the invasive vertical growth phase (VGP), survival rates decrease to 15%. The targets of many clinical trials are the known genetic and molecular mechanisms involved in melanoma progression, with the most common oncogenic mutation being the BRAFV600E. Howev...
This review article deals with the analysis and the detection of the morphological features associated with somatic mutations, mostly BRAFV600E mutation, on both cytological and histological samples of carcinomas. Few authors demonstrated that some architectural and specific cellular findings (i.e. polygonal eosinophilic cells defined as "plump cells" and sickle-shaped nuclei) are able to predi...
Major advances have been made in understanding the pathogenesis of Erdheim-Chester disease (ECD) leading to novel treatment strategies. Targeted therapies such as BRAF inhibition have shown a significant impact on disease management, emphasizing the importance of the activated mitogen-associated protein kinase pathway in this disease. However, incomplete responsiveness, potentially limiting adv...
BACKGROUND BRAF mutations have been well described in non-small cell lung cancer (NSCLC) for several years, but the clinical features of patients harboring BRAF mutations are still not well described. We performed a meta-analysis to identify common clinical features in NSCLC patients carrying BRAF mutations. METHODS We identified clinical studies that examined the association between BRAF mut...
Adrenal oncocytoma (AO) is an extremely rare adrenocortical neoplasm and little is known about its malignant potential, secretory properties, and hereditary origin. We present the case of a benign AO with concomitant incidentally found papillary thyroid cancer (PTC) and review similar cases in the literature. Immunohistochemistry and next-generation sequencing (NGS) were performed. A 66-year-ol...
Background Activating mutations or structural rearrangements in BRAF are identified in roughly 75% of all pediatric low-grade astrocytomas (PLGAs). However, first-generation RAF inhibitors approved for adult melanoma have poor blood-brain penetrance and are only effective on tumors that express the canonical BRAFV600E oncoprotein, which functions as a monomer. These drugs (type I antagonists th...
Введение. Папиллярный рак щитовидной железы (ПРЩЖ) является наиболее распространенной опухолевой патологией среди новообразований эндокринных органов. Ключевыми молекулярными механизмами активация онкогена b-RAF и MAPK сигнального пути с формированием агрессивного инвазивного метастатического потенциала. Ко-активаторы стероидных рецепторов SRC-1, SRC-3 являются факторами широкой специфичностью ...
The BRAF inhibitor encorafenib, in combination with cetuximab (EC), has recently been approved for patients BRAFV600E-mutated metastatic colorectal cancer (BRAFV600E-mCRC) after prior systemic therapy. As the is first inhibitor-based regimen BRAFV600E-mCRC goal of this analysis was to explore novel and distinctive data visualization outputs enable a potentially more practical interpretation pre...
Although cancer outcome results from the interplay between genetics and environment, researchers are making a great effort for applying molecular biology in the prognostication of differentiated thyroid cancer (DTC). Nevertheless, role of molecular characterisation in the prognostic setting of DTC is still nebulous. Among the most common and well-characterised genetic alterations related to DTC...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید